People who cease taking GLP-1 obesity drugs, which include semaglutide (Wegovy) and tirzepatide (Zepbound), typically regain an average of nearly a pound a month, ultimately gaining back all the weight they lost within two years, according to a review of 37 earlier studies
Basdas R, Martnez-Cereijo JM, Fernndez L, Reija L, Cabaleiro A, Bravo SB, et al
This has always been part of how American medicine works, for semaglutide and for thousands of other drugs, particularly when a patient needs a formulation, strength, or delivery method that isn't available as a standard commercial product, or when the commercial product is priced out of reach for a large share of the population who could otherwise benefit from it
Initial eligibility is restricted to people with a BMI of 40 or above (adjusted for ethnicity) and at least four weight-related health conditions
Because of these combined effects, portion sizes naturally become smaller and people find they can no longer finish meals they previously considered normal
